Eur Rev Med Pharmacol Sci 2021; 25 (7): 2829-2829

DOI: 10.26355/eurrev_202104_25533

MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9

Y. Wu, Y. Wu, X.-Y. Chen, Y.-X. Niu, F.-Z. Lv, W. Gao

Department of Thoracic Surgery, Shanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital, Shanghai, China.


Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, “MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9, by Y. Wu, Y. Wu, X.-Y. Chen, Y.-X. Niu, F.-Z. Lv, W. Gao, published in Eur Rev Med Pharmacol Sci 2020; 24 (17): 8893-8901–DOI: 10.26355/eurrev_202009_22830–PMID: 32964979” has been withdrawn.

The Publisher apologizes for any inconvenience this may cause.

MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9

Free PDF Download

To cite this article

Y. Wu, Y. Wu, X.-Y. Chen, Y.-X. Niu, F.-Z. Lv, W. Gao
MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 7
Pages: 2829-2829
DOI: 10.26355/eurrev_202104_25533